Nian Wu, Ph.D.
Chief Executive Officer

Founder and lead inventor of the Liposeuticals technology platform, Dr. Nian Wu has over 30 years of experience in pharmaceutical product R&D, product formulation and project management. He was formerly a Research Faculty and Group Head from 2004 to 2013 at Memorial Sloan-Kettering Cancer Center (MSKCC) and adjunct professor at Gerstner Sloan-Kettering Graduate School of Biomedical Sciences in New York City, and prior to that worked at Schering-Plough (now Merck & Co.), Wyeth-Ayerst (now Pfizer), and Alpharma (also now part of Pfizer). He has published over 60 research articles and is listed as an inventor or co-inventor on over 20 patents. He earned a master degree in chemistry from the University of Scranton in Scranton, PA, obtained his Ph.D. in chemistry from the State University of New York and did his postdoctoral work in the University of Illinois at Urbana-Champaign.

Yan Liu. MBA/MSc
Sr. Director, Buniess development

Ms. Yang has a strong leadership and extensive experience in both global clinical and business development through her contributions to multiple projects with Allergan, Sanofi-Aventis, Eisai, Synergy Pharmaceuticals, Mankind, Target Health and Yuanxing Gene Technology Co. Yan has a broad background and drug development expertise in the areas of biostatistics and clinical trial management across CNS, oncology, cardiovascular and rare diseases. She played critical roles in two successful new drug applications, AFREZZ and TULANE. Yan has been in the leading roles in business development with Target Health and Yuanxing Gene Technology where she identified and executed in-licensing opportunities of novel therapeutic assets, as well as partnering and building collaborations with key pharma companies. Yan holds Master of Statistics from University of Ottawa and MBA from Kellogg School of Management at Northwestern University.

James Chen, Ph.D.
Vice President

Dr. Chen has served as our Vice President of Product Development since November 2018 and leads the product development of our CNS and Oncology programs. He has over 25 years of experience in pharmaceutical R&D. Before joining LipoSeuticals, Dr. Chen conducted drug research and development at Schering-Plough, Merck and BMS. He was responsible for the development of medicines in multiple therapeutic areas, including CNS, oncology and hepatitis C infection. Dr. Chen is author or co-author of over 30 articles in top peer viewed journals and he received her Ph.D. degree in chemistry from the State University of New York.

Chris Ye, Ph.D.
Senior Principal Scientist

Dr. Ye has more than 20 years’ experience in the field of chemistry and pharmaceuticals. Dr. Ye has a broad background and knowledge in multi-step organic synthesis, process optimization/ scale up synthesis. Expertise in synthesis of heterocyclic compounds, boronic acids and fluorine chemistry. He has been working in prestigious institution and various pharmaceutical and chemical industries. Dr. Ye obtained his Ph. D. in chemistry from Chinese Academy of Sciences and had his postdoctoral training at University of Idaho. Dr. Ye co-authored 10 articles in top peer viewed journals. Dr. Ye is the key person and serves as a technical director for the sugar-lipid polymer production.

Lan-Bo Chen, Ph.D.
Board Director and Scientific Advisor

Dr. Chen is Professor Emeritus of Pathology at Harvard Medical School. He received his Ph.D. in cell biology from the Massachusetts Institute of Technology and elected as an academician of the Academia Sinica of Taiwan. He is the author of over 250 academic publications and is the founder of several successful biotechnology companies and ventures, including Fuji ImmunoPharmaceuticals Corp. and Shionogi BioResearch Corp. (both with Nobel laureate Dr. Susumu Tonegawa); Caxton Life Science Partners; Taiwan Global BioFund; TaiMed Biologics; Mevion Medical Systems; Cancer BioScience; Cancer Genetics; Kava Pharmaceuticals; SinglePixel BioMedical; Quercegen Pharma; Madrigal/Synta Pharmaceuticals and Sequential Medicine. Dr. Chen has served as a Senior Consultant for numerous large pharmaceutical firms, and has led the development or consulted for more than a dozen drugs and drug candidates.

Joseph Vinson, Ph.D.
Board Director and Scientific Advisor

Dr. Vinson is Professor Emeritus of Chemistry at University of Scranton. He received his Ph.D. in Chemistry from the Iowa State University. His research has been featured in Prevention, Psychology Today, Consumer Reports, AARP, Tufts Health & Nutrition Newsletter, US News & World Report and lam pooned in a cartoon in Time magazine. He has appeared on TV-Good Morning America Sunday and radio-NPR “All Things Considered” and “The Peoples Pharmacy,” as well as being mentioned by Jay Leno and Rush Limbaugh. Dr. Vinson is the author of over 70 publications. His research interests are wide-ranging and include drug analysis in physiological fluids and the effect of vitamins, minerals, and antioxidants on nutrition and health.